A higher rate of multiple conditions associated with poor health among young people with high mean daily smartphone usage.
AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes